Want to see PRME full AI Analyst Report?
Top Page
Prime Medicine, Inc.
(NASDAQ:PRME)
Select Model
Select Model
Rating:47Neutral
Price Target:
$3.50
▼(-2.23% Downside)
Action:Reiterated
Date:10/09/26
The score is primarily held back by weak financial performance (minimal and declining revenue, large losses, heavy cash burn, and rising leverage with shrinking equity). Technicals provide some support due to a price trend above key moving averages and moderately positive momentum, but valuation remains constrained by negative earnings and no dividend.
Positive Factors
Prime Editing Platform
Prime Medicine has a defined technology platform aimed at directly editing DNA to address genetic diseases. This creates a focused development strategy and preserves the possibility of building multiple therapies from a common scientific foundation if clinical progress supports broader application.
Negative Factors
Small and Declining Revenue
Prime Medicine lacks a meaningful established commercial revenue base, while reported TTM revenue has declined from the prior period. This limits internal funding capacity and leaves the business dependent on successful development, partnerships, or other financing sources to support its platform.
Read all positive and negative factors
Positive Factors
Negative Factors
Prime Editing Platform
Prime Medicine has a defined technology platform aimed at directly editing DNA to address genetic diseases. This creates a focused development strategy and preserves the possibility of building multiple therapies from a common scientific foundation if clinical progress supports broader application.
Read all positive factors
Prime Medicine, Inc. (PRME) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$654.77M
Dividend Yield6.8%
Average Volume (3M)3.98M
Price to Earnings (P/E)―
Beta (1Y)2.84
Revenue Growth-17.90%
EPS Growth32.10%
CountryUS
Employees146
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.10
Shares Outstanding181,376,860
10 Day Avg. Volume5,901,661
30 Day Avg. Volume3,975,379
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)4.27
Price to Sales (P/S)111.44
P/FCF Ratio-3.09
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue164.83
Enterprise Value/Gross Profit-16.07
Enterprise Value/Ebitda-3.72
Forecast
1Y Price Target
$7.67Price Target Upside114.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.97
Revenue Forecast (FY)$8.86M
Prime Medicine, Inc. Business Overview & Revenue Model
Company Description
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combin...
How the Company Makes Money
Prime Medicine has not broadly disclosed a stable, product-based commercial revenue stream; as a clinical-stage biotech, its revenue, when reported, is generally expected to come from payments received under collaboration and licensing arrangement...
Prime Medicine, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.07M | 4.63M | 2.98M | 0.00 | 0.00 | 0.00 |
| Gross Profit | -41.77M | -2.69M | 2.98M | 0.00 | 0.00 | 0.00 |
| EBITDA | -180.49M | -195.76M | -189.75M | -186.64M | -120.55M | -165.28M |
| Net Income | -187.89M | -201.14M | -195.88M | -198.13M | -121.82M | -165.37M |
Balance Sheet | ||||||
| Total Assets | 249.04M | 342.73M | 297.51M | 193.85M | 360.31M | 301.86M |
| Cash, Cash Equivalents and Short-Term Investments | 95.07M | 177.68M | 190.44M | 121.67M | 293.92M | 269.62M |
| Total Debt | 112.48M | 116.43M | 40.79M | 13.63M | 28.75M | 10.41M |
| Total Liabilities | 209.23M | 221.87M | 144.36M | 60.78M | 44.04M | 62.30M |
| Stockholders Equity | 39.81M | 120.87M | 153.15M | 133.07M | 316.27M | 239.56M |
Cash Flow | ||||||
| Free Cash Flow | -156.85M | -167.09M | -130.16M | -174.14M | -147.92M | -38.23M |
| Operating Cash Flow | -156.05M | -162.56M | -122.86M | -165.41M | -131.83M | -34.08M |
| Investing Cash Flow | 3.63M | -108.76M | 68.46M | 18.71M | -47.10M | -73.63M |
| Financing Cash Flow | 146.07M | 151.51M | 195.88M | 655.00K | 181.49M | 269.28M |
Prime Medicine, Inc. Technical Analysis
Positive
3.58
Price Trends
3.30
Positive
3.29
Positive
3.48
Positive
Market Momentum
0.10
Negative
55.02
Neutral
70.28
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRME, the sentiment is Positive. The current price of 3.58 is above the 20-day moving average (MA) of 3.25, above the 50-day MA of 3.30, and above the 200-day MA of 3.48, indicating a bullish trend. The MACD of 0.10 indicates Negative momentum. The RSI at 55.02 is Neutral, neither overbought nor oversold. The STOCH value of 70.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PRME.
Prime Medicine, Inc. Risk Analysis
Prime Medicine, Inc. disclosed 80 risk factors in its most recent earnings report. Prime Medicine, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Prime Medicine, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $3.94B | -11.45 | -42.27% | ― | 23.86% | 19.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $1.35B | -9.80 | -56.19% | ― | -32.27% | -21.09% | |
49 Neutral | $228.40M | -1.44 | -48.40% | ― | 15.98% | -40.75% | |
48 Neutral | $1.08B | -4.06 | -47.04% | ― | -65.40% | -164.71% | |
47 Neutral | $654.77M | -3.28 | -188.27% | 6.80% | -17.90% | 32.10% | |
41 Neutral | $784.32M | -3.45 | -134.49% | ― | ― | 28.46% |
* Healthcare Sector Average
PRME
Prime Medicine, Inc.
3.61
-2.04
-36.11%
IMTX
Immatics
7.21
-2.88
-28.54%
RLAY
Relay Therapeutics
17.98
11.71
186.76%
TSHA
Taysha Gene Therapies
4.14
-0.91
-18.02%
SANA
Sana Biotechnology
2.62
-1.72
-39.63%
UPB
Upstream Bio, Inc.
4.17
-15.91
-79.23%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.